Portola Pharmaceuticals

Biopharma takeovers show quantity, if not quality
EP Vantage
Mon, 07/13/20 - 11:13 am
COVID-19
pandemic
M&A
Novo Nordisk
Corvidia
Gilead Sciences
Pionyr
Alexion
Portola Pharmaceuticals
Menarini
Stemline Therapeutics
Shionogi
Tetra Therapeutics
Alexion Pharma to Buy Portola for $18-Share, or $1.41 Billion
TheStreet.com
Tue, 05/5/20 - 11:08 am
Alexion
M&A
Portola Pharmaceuticals
AndexXa
Portola's stock falls on weak Andexxa sales
Marketwatch
Sat, 01/11/20 - 11:20 pm
Portola Pharmaceuticals
AndexXa
earnings
3 Key Takeaways From Portola Pharmaceuticals' Quarterly Results
Motley Fool
Sun, 05/12/19 - 01:29 pm
Portola Pharmaceuticals
earnings
Factor Xa inhibition
Andexxa will go nationwide with FDA nod on Portola's commercial production of the bleeding antidote
Fierce Pharma
Wed, 01/2/19 - 11:38 am
Portola Pharmaceuticals
AndexXa
Pfizer
Bristol-Myers Squibb
JNJ
Bayer
FDA
anticoagulant reversal
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Yahoo/Benzinga
Mon, 12/31/18 - 11:57 am
Goldman Sachs
Portola Pharmaceuticals
AndexXa
Sesen Bio
Vicinium
Is an Acquisition in Portola Pharmaceuticals' Future?
Motley Fool
Tue, 06/5/18 - 10:57 pm
Portola Pharmaceuticals
M&A
Portola Pharma CEO Bill Lis Plans to Retire from Company, Board
Xconomy
Mon, 06/4/18 - 10:07 pm
Portola Pharmaceuticals
Pharma CEOs
Bill Lis
FDA Approval of Portola Drug Puts Firm in Line for $100M Payday
Xconomy
Fri, 05/4/18 - 06:50 pm
anticoagulant reversal
FDA
Portola Pharmaceuticals
AndexXa
In a comeback, Portola scores FDA accelerated approval for once-rejected Andexxa
Endpoints
Fri, 05/4/18 - 10:13 am
FDA
Portola Pharmaceuticals
andexanet alfa
AndexXa
blood thinners
3 Small-Cap Biotech Stocks With Big Catalysts in May
Motley Fool
Mon, 04/30/18 - 09:16 pm
Achaogen
plazomicin
Akcea Therapeutics
Volanesorsen
Portola Pharmaceuticals
AndexXa
EMA’s CHMP Rejects Two Drugs Approved by US FDA in 2017
RAPS.org
Fri, 03/23/18 - 10:10 am
EMA
Europe
CHMP
FDA
Bevyxxa
Portola Pharmaceuticals
Dexxience
Tymlos
Radius Health
Eladynos
5 Biotech Stocks That Could Be Bought Out in 2018
Yahoo/Motley Fool
Sun, 01/14/18 - 09:38 am
biotech stocks
Portola Pharmaceuticals
Tesaro
Bluebird Bio
Esperion Therapeutics
GlycoMimetics
3 Biotechs Launching Their First Commercial Drugs in 2018
Motley Fool
Mon, 01/1/18 - 03:13 pm
biotech
drug launches
Flexion
Zilretta
osteoarthritis of the knee
La Jolla Pharmaceutical
Giapreza
shock
Portola Pharmaceuticals
Bevyxxa
venous thromboembolism
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
EP Vantage
Tue, 08/22/17 - 09:55 am
R&D
Kite Pharma
Incyte
Portola Pharmaceuticals
DBV Technologies
Axovant
AveXis
Take two: Portola's reversal agent secures FDA review
BioPharma Dive
Wed, 08/16/17 - 10:14 am
Portola Pharmaceuticals
FDA
AndexXa
anticoagulant reversal
[video]How Portola Is Looking to Change the Anticoagulant Game
Motley Fool
Tue, 07/11/17 - 09:55 am
Portola Pharmaceuticals
anticoagulants
Bevyxxa
JNJ
Pfizer
3 Mid-Cap Biotech Stocks That May Be Red-Hot Takeover Candidates
Motley Fool
Wed, 07/5/17 - 07:08 pm
biotech
M&A
Exelixis
Portola Pharmaceuticals
Intercept Pharmaceuticals
These 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing?
Motley Fool
Tue, 06/27/17 - 11:52 pm
biotech
Omeros
Cara Therapeutics
Portola Pharmaceuticals
Portola Pharmaceuticals' FDA Nod Could Spark M&A Interest
Motley Fool
Sun, 06/25/17 - 10:46 am
Portola Pharmaceuticals
FDA
M&A
Bevyxxa

Pages